EMA Authorised: Repaglinide Accord (repaglinide) — Accord Healthcare S.L.U.

View source ↗

Summary

The European Medicines Agency authorised Accord Healthcare S.L.U.'s Repaglinide Accord for the treatment of type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Repaglinide Accord (repaglinide)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Accord Healthcare S.L.U.. Decision date: 23/09/2024